HRP20090641T1 - Pripravci modulatora 5ht2c receptora i postupci uporabe - Google Patents
Pripravci modulatora 5ht2c receptora i postupci uporabe Download PDFInfo
- Publication number
- HRP20090641T1 HRP20090641T1 HR20090641T HRP20090641T HRP20090641T1 HR P20090641 T1 HRP20090641 T1 HR P20090641T1 HR 20090641 T HR20090641 T HR 20090641T HR P20090641 T HRP20090641 T HR P20090641T HR P20090641 T1 HRP20090641 T1 HR P20090641T1
- Authority
- HR
- Croatia
- Prior art keywords
- halogen
- 8alkyl
- methyl
- composition according
- benzazepine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 24
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title claims abstract 9
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title claims abstract 9
- 238000000034 method Methods 0.000 title claims 3
- 229940075993 receptor modulator Drugs 0.000 title 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims abstract 16
- 229960003562 phentermine Drugs 0.000 claims abstract 8
- 239000000018 receptor agonist Substances 0.000 claims abstract 8
- 229940044601 receptor agonist Drugs 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 239000012453 solvate Substances 0.000 claims abstract 5
- 238000011282 treatment Methods 0.000 claims abstract 4
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 150000002367 halogens Chemical class 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 21
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 230000037406 food intake Effects 0.000 claims 4
- 235000012631 food intake Nutrition 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000002485 serotonin 2C agonist Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 3
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- -1 cyclopenyl Chemical group 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- SJJIKXOJEDKQRJ-UHFFFAOYSA-N 7-chloro-8-methoxy-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C)C2=C1C=C(OC)C(Cl)=C2 SJJIKXOJEDKQRJ-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 150000002460 imidazoles Chemical class 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- DHQGBGMOFXIOBH-MRVPVSSYSA-N (2r)-1-(5-chloro-2-fluorophenyl)-2-methylpiperazine Chemical group C[C@@H]1CNCCN1C1=CC(Cl)=CC=C1F DHQGBGMOFXIOBH-MRVPVSSYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- VDDJHHQYKKCCIO-UHFFFAOYSA-N 5-ethyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC=C(C(F)(F)F)C=C12 VDDJHHQYKKCCIO-UHFFFAOYSA-N 0.000 claims 1
- LGUJJJJNBBUBHT-UHFFFAOYSA-N 5-ethyl-7-iodo-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC=C(I)C=C12 LGUJJJJNBBUBHT-UHFFFAOYSA-N 0.000 claims 1
- GBYLNYMTYZRQLE-UHFFFAOYSA-N 5-methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(C(F)(F)F)C=C12 GBYLNYMTYZRQLE-UHFFFAOYSA-N 0.000 claims 1
- TTXLZSFANXGSGY-UHFFFAOYSA-N 7,8-dichloro-5-ethyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC(Cl)=C(Cl)C=C12 TTXLZSFANXGSGY-UHFFFAOYSA-N 0.000 claims 1
- KTCVEIAEKPSBCJ-UHFFFAOYSA-N 7,8-dichloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC(Cl)=C(Cl)C=C12 KTCVEIAEKPSBCJ-UHFFFAOYSA-N 0.000 claims 1
- FZAXXXCRTZYHAH-UHFFFAOYSA-N 7-bromo-5-ethyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC=C(Br)C=C12 FZAXXXCRTZYHAH-UHFFFAOYSA-N 0.000 claims 1
- KRBZRTWDEJCQIL-UHFFFAOYSA-N 7-bromo-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(Br)C=C12 KRBZRTWDEJCQIL-UHFFFAOYSA-N 0.000 claims 1
- DNLSOPHLIKCIIV-UHFFFAOYSA-N 7-chloro-5-ethyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC=C(Cl)C=C12 DNLSOPHLIKCIIV-UHFFFAOYSA-N 0.000 claims 1
- FAVBYFITEFEUJI-UHFFFAOYSA-N 7-chloro-5-ethyl-8-fluoro-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC(F)=C(Cl)C=C12 FAVBYFITEFEUJI-UHFFFAOYSA-N 0.000 claims 1
- XTTZERNUQAFMOF-UHFFFAOYSA-N 7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-UHFFFAOYSA-N 0.000 claims 1
- AELPHXGUKIVCSY-UHFFFAOYSA-N 7-chloro-8-fluoro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC(F)=C(Cl)C=C12 AELPHXGUKIVCSY-UHFFFAOYSA-N 0.000 claims 1
- MWDDRGPUDJHEAN-UHFFFAOYSA-N 7-iodo-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(I)C=C12 MWDDRGPUDJHEAN-UHFFFAOYSA-N 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical group C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Steroid Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866704P | 2004-12-23 | 2004-12-23 | |
| US68890105P | 2005-06-08 | 2005-06-08 | |
| PCT/US2005/046654 WO2006071740A2 (en) | 2004-12-23 | 2005-12-21 | 5ht2c receptor modulator compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090641T1 true HRP20090641T1 (hr) | 2010-01-31 |
Family
ID=36615431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090641T HRP20090641T1 (hr) | 2004-12-23 | 2009-12-02 | Pripravci modulatora 5ht2c receptora i postupci uporabe |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US8153621B2 (de) |
| EP (3) | EP1833473B1 (de) |
| JP (1) | JP4886700B2 (de) |
| KR (3) | KR20130087622A (de) |
| CN (3) | CN102627607A (de) |
| AT (1) | ATE442135T1 (de) |
| AU (1) | AU2005322183B2 (de) |
| BR (1) | BRPI0515862A2 (de) |
| CA (1) | CA2588941A1 (de) |
| CY (1) | CY1109629T1 (de) |
| DE (1) | DE602005016601D1 (de) |
| DK (1) | DK1833473T3 (de) |
| EA (2) | EA015012B1 (de) |
| ES (1) | ES2331656T3 (de) |
| HK (1) | HK1102766A1 (de) |
| HR (1) | HRP20090641T1 (de) |
| IL (2) | IL183565A0 (de) |
| NZ (2) | NZ555482A (de) |
| PL (1) | PL1833473T3 (de) |
| PT (1) | PT1833473E (de) |
| RS (1) | RS50997B (de) |
| SG (1) | SG158168A1 (de) |
| SI (1) | SI1833473T1 (de) |
| WO (1) | WO2006071740A2 (de) |
| ZA (1) | ZA200705165B (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080103179A1 (en) | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| WO2005003096A1 (en) | 2003-06-17 | 2005-01-13 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
| ES2571220T3 (es) | 2003-06-17 | 2016-05-24 | Arena Pharm Inc | Clorhidrato de 8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepina |
| US8168624B2 (en) | 2004-12-21 | 2012-05-01 | Arena Pharmaceuticals, Inc. | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| CN102627607A (zh) | 2004-12-23 | 2012-08-08 | 艾尼纳制药公司 | 5HT2c受体调节剂组合物和使用方法 |
| CA2619450C (en) | 2005-09-01 | 2013-10-22 | Eli Lilly And Company | 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| ATE437859T1 (de) | 2005-09-01 | 2009-08-15 | Lilly Co Eli | 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten |
| ES2397400T3 (es) | 2005-09-01 | 2013-03-06 | Eli Lilly & Company | 6-arilalquilamino-2,3,4,5-tetrahidro-1H-benzo[D]azepinas como agonistas del receptor 5-HT2C |
| JP5165568B2 (ja) | 2005-09-01 | 2013-03-21 | イーライ リリー アンド カンパニー | ５−ＨＴ２Ｃ受容体アゴニストとしての６−置換−２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン |
| CA2646044A1 (en) | 2006-04-03 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
| WO2007140213A1 (en) | 2006-05-26 | 2007-12-06 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| CA2692440A1 (en) * | 2006-07-20 | 2008-01-24 | Cascade Therapeutics Inc. | Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
| SG177128A1 (en) | 2006-12-05 | 2012-01-30 | Arena Pharm Inc | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
| US8822727B2 (en) * | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
| US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| AU2010249472B2 (en) | 2009-05-22 | 2015-09-10 | AbbVie Deutschland GmbH & Co. KG | Modulators of 5-HT receptors and methods of use thereof |
| US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
| EP2571353B1 (de) | 2010-05-21 | 2017-08-09 | AbbVie Inc. | 5-ht-rezeptor-modulatoren und verfahren zu ihrer verwendung |
| WO2011153206A1 (en) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-ht2c receptor agonists |
| WO2012030957A2 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| MX2013002418A (es) | 2010-09-01 | 2013-08-01 | Arena Pharm Inc | Administracion de lorcaserina a individuos con daño renal. |
| WO2012030953A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| SG188363A1 (en) * | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Fast-dissolve dosage forms of 5-ht2c agonists |
| MX2013002422A (es) | 2010-09-01 | 2013-05-17 | Arena Pharm Inc | Sales de lorcaserina con acidos opticamente activos. |
| CN103189053A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 用于体重控制的5-ht2c激动剂的调节释放剂型 |
| MY181736A (en) | 2012-10-09 | 2021-01-05 | Arena Pharm Inc | Method of weight management |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN105622511B (zh) * | 2014-11-03 | 2018-01-23 | 北京瑞都医药科技有限公司 | 一种减肥药物及其制备方法 |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH498122A (de) | 1968-02-09 | 1970-10-31 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates |
| CH481110A (de) | 1967-02-17 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen |
| GB1234399A (de) * | 1967-10-26 | 1971-06-03 | ||
| CH500194A (de) | 1968-02-15 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Tetrahydroazepinderivaten |
| US4233217A (en) * | 1968-03-11 | 1980-11-11 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines |
| CA974989A (en) | 1968-03-11 | 1975-09-23 | Wallace And Tiernan Inc. | Process for preparing 1,2,4,5-tetrahydro-3h,3-benzazepines and products obtained thereby |
| FR314F (de) | 1968-03-22 | 1970-05-25 | ||
| FR7736M (de) | 1968-09-02 | 1970-03-09 | ||
| US3716639A (en) | 1970-03-11 | 1973-02-13 | Ciba Geigy Corp | Anorexigenic tetrahydrobenzazepines |
| US3795683A (en) * | 1970-08-19 | 1974-03-05 | Hoffmann La Roche | 2,3,4,5-tetrahydro-1h-3-benzazepines |
| US3795663A (en) | 1972-05-01 | 1974-03-05 | Commercial Solvents Corp | Recovery of bacitracin |
| LU65954A1 (de) * | 1972-08-25 | 1974-03-07 | ||
| US4210749A (en) * | 1974-11-12 | 1980-07-01 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines |
| US4111957A (en) | 1977-02-02 | 1978-09-05 | Smithkline Corporation | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| US4108989A (en) * | 1977-04-01 | 1978-08-22 | Smithkline Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones |
| CA1090797A (en) | 1978-06-20 | 1980-12-02 | Kenneth G. Holden | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds |
| AU515236B2 (en) | 1978-06-26 | 1981-03-26 | Smithkline Corporation | Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives |
| ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
| DE3002989A1 (de) | 1980-01-29 | 1981-07-30 | Hoechst Ag, 6000 Frankfurt | Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels |
| US4477378A (en) * | 1980-02-05 | 1984-10-16 | Schering Corp. | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
| ZA827887B (en) | 1981-11-27 | 1983-11-30 | Smithkline Beckman Corp | Pharmaceutical compositions and method of producing alpha2 antagonism |
| EP0161350A1 (de) | 1981-11-27 | 1985-11-21 | Smithkline Beckman Corporation | Verfahren zur Herstellung von Benzazepinen |
| FR2525603A1 (fr) | 1982-04-27 | 1983-10-28 | Adir | Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique |
| US4988690A (en) | 1982-06-14 | 1991-01-29 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof |
| DE3418270A1 (de) | 1984-05-17 | 1985-11-21 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US4541954A (en) | 1984-09-05 | 1985-09-17 | Smithkline Beckman Corporation | Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| EP0204349A3 (de) | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB8610668D0 (en) | 1986-05-01 | 1986-06-04 | Pfizer Ltd | Anti-arrhythmia agents |
| US4762845A (en) * | 1986-05-21 | 1988-08-09 | Abbott Laboratories | 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids |
| EP0285287A3 (de) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | Verwendung von 3-Benzazepinen zur Behandlung von gastrointestinalen Mobilitätsstörungen |
| US5247080A (en) * | 1987-03-27 | 1993-09-21 | Schering Corporation | Substituted benzazepines useful as intermediates for producing pharmaceutically active compounds |
| US5015639A (en) * | 1987-03-27 | 1991-05-14 | Schering Corporation | Substituted benzazepines, their preparation and pharmaceutical compositions containing them |
| PH27337A (en) | 1987-03-27 | 1993-06-08 | Schering Corp | Substituted benzazepines their preparation and pharmaceutical compositions containing them |
| DE3710904A1 (de) | 1987-04-01 | 1988-10-13 | Siemens Ag | Verfahren und anordnung zur auswertung einer analogen elektrischen messgroesse |
| WO1988007858A1 (en) | 1987-04-09 | 1988-10-20 | Smithkline Beckman Corporation | Sulfinyl and sulfonyl substituted 3-benzazepines |
| US4957914A (en) * | 1987-05-15 | 1990-09-18 | Syntex (U.S.A.) Inc. | 1,9-alkano-bridged-2,3,4,5-tetrahydro-1H-3-benzazepines |
| DK107688D0 (da) | 1988-03-01 | 1988-03-01 | Novo Industri As | Carbaminsyreestere af substituerede 7-hydroxy-2,3,4,5-tetrahydro-1h-3-benzazepiner |
| US5422355A (en) * | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
| US5178786A (en) * | 1989-08-04 | 1993-01-12 | The Lubrizol Corporation | Corrosion-inhibiting compositions and functional fluids containing same |
| AU8201591A (en) | 1990-06-15 | 1992-01-07 | Schering Corporation | 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them |
| EP0489166A4 (en) | 1990-06-21 | 1992-11-19 | Nippon Shokubai Kagaku Kogyo Co. Ltd. | Process for producing n-substituted aziridine compound |
| US5275915A (en) * | 1991-06-05 | 1994-01-04 | Dainippon Ink And Chemicals, Inc. | Developer for light-sensitive material |
| PT100602A (pt) | 1991-06-21 | 1993-09-30 | Smithkline Beecham Plc | Uso de derivados de tetra-hidrobenzazepinas, derivados de tetra-hidrobenzazepinas,sua preparacao e composicoes farmaceuticas que os contem |
| GB9116824D0 (en) | 1991-08-05 | 1991-09-18 | Smithkline Beecham Corp | Chemical compounds |
| KR0184911B1 (ko) * | 1991-11-25 | 1999-05-01 | 알렌 제이. 스피겔 | 인돌유도체 |
| EP0558824A1 (de) * | 1992-02-04 | 1993-09-08 | Duphar International Research B.V | Verfahren zur Herstellung von vicinalen Aminoalkoholen und deren optisch aktive O-geschützte Derivate |
| JPH05339263A (ja) | 1992-06-08 | 1993-12-21 | Wakunaga Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
| JPH0662574A (ja) | 1992-08-05 | 1994-03-04 | Fuji Electric Co Ltd | 電力変換装置の冷却構造 |
| JPH06298746A (ja) | 1993-04-19 | 1994-10-25 | Showa Denko Kk | 環状イミド酸エステルの製造法 |
| CA2166100A1 (en) * | 1993-06-23 | 1995-01-05 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| US5387685A (en) * | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
| GB9322976D0 (en) * | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
| DE4419246A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4419247A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie |
| DE4419315A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4429079A1 (de) | 1994-08-17 | 1996-02-22 | Thomae Gmbh Dr K | Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JPH08134048A (ja) | 1994-11-08 | 1996-05-28 | Sumitomo Chem Co Ltd | オキサゾリン類の製造法 |
| JPH0930960A (ja) | 1995-07-18 | 1997-02-04 | Takasago Internatl Corp | 真菌感染症治療剤 |
| JPH0987258A (ja) | 1995-09-28 | 1997-03-31 | Sumitomo Chem Co Ltd | オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法 |
| CA2190708A1 (en) * | 1995-12-08 | 1997-06-09 | Johannes Aebi | Aminoalkyl substituted benzo-heterocyclic compounds |
| US5925651A (en) * | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5691362A (en) * | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
| DE69941777D1 (de) * | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| JP3603177B2 (ja) | 1998-03-26 | 2004-12-22 | 参天製薬株式会社 | 新規ウレア誘導体 |
| EP0987235B1 (de) | 1998-08-25 | 2003-03-12 | MERCK PATENT GmbH | Verfahren zur Umsetzung von Arenen oder Alkenen mit Iodalkenen, Aryliodiden oder Arendiazoniumsalzen |
| EP1074549B1 (de) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten |
| DE60006618T2 (de) | 1999-08-06 | 2004-09-23 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten |
| US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| DE10003708A1 (de) * | 2000-01-28 | 2001-08-02 | Solvent Innovation Gmbh | Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form |
| CZ299561B6 (cs) * | 2000-06-30 | 2008-09-03 | Glaxo Group Limited | Chinazolinaminový derivát a farmaceutický prostredek |
| DE10057751A1 (de) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| AU2002367323A1 (en) * | 2001-12-28 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Benzothieno (3,2- |
| CA2471880A1 (en) * | 2001-12-28 | 2003-07-17 | Bayer Pharmaceuticals Corporation | 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| EP1496838B1 (de) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituierte amide |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| DE10261131A1 (de) * | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| ES2571220T3 (es) * | 2003-06-17 | 2016-05-24 | Arena Pharm Inc | Clorhidrato de 8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepina |
| WO2005003096A1 (en) * | 2003-06-17 | 2005-01-13 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases |
| KR20060065584A (ko) | 2003-06-20 | 2006-06-14 | 아레나 파마슈티칼스, 인크. | Ｎ-페닐-피페라진 유도체 및 5ｈｔ2ｃ 수용체 관련 질환의예방 또는 치료 방법 |
| US20080009478A1 (en) * | 2003-10-22 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases |
| US20070275949A1 (en) * | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
| JP2005260592A (ja) * | 2004-03-11 | 2005-09-22 | Fujitsu Ltd | アンテナ装置、指向性制御方法及び通信装置 |
| AU2005268781A1 (en) | 2004-08-02 | 2006-02-09 | Genmedica Therapeutics Sl | Compounds for inhibiting copper-containing amine oxidases and uses thereof |
| WO2006043710A1 (ja) | 2004-10-19 | 2006-04-27 | Reverse Proteomics Research Institute Co., Ltd. | 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法 |
| US8168624B2 (en) | 2004-12-21 | 2012-05-01 | Arena Pharmaceuticals, Inc. | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| CN102627607A (zh) * | 2004-12-23 | 2012-08-08 | 艾尼纳制药公司 | 5HT2c受体调节剂组合物和使用方法 |
| CA2646044A1 (en) | 2006-04-03 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
| SG177128A1 (en) | 2006-12-05 | 2012-01-30 | Arena Pharm Inc | Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof |
| US8822727B2 (en) | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
-
2005
- 2005-12-21 CN CN2012100775843A patent/CN102627607A/zh active Pending
- 2005-12-21 RS RSP-2009/0524A patent/RS50997B/sr unknown
- 2005-12-21 EP EP05855247A patent/EP1833473B1/de active Active
- 2005-12-21 BR BRPI0515862-1A patent/BRPI0515862A2/pt not_active IP Right Cessation
- 2005-12-21 KR KR1020137018336A patent/KR20130087622A/ko not_active Application Discontinuation
- 2005-12-21 CA CA002588941A patent/CA2588941A1/en not_active Withdrawn
- 2005-12-21 NZ NZ555482A patent/NZ555482A/en not_active IP Right Cessation
- 2005-12-21 KR KR1020077016812A patent/KR101426850B1/ko not_active IP Right Cessation
- 2005-12-21 CN CN2005800437436A patent/CN101123955B/zh not_active Expired - Fee Related
- 2005-12-21 CN CN201210077623XA patent/CN102631349A/zh active Pending
- 2005-12-21 EA EA200701357A patent/EA015012B1/ru not_active IP Right Cessation
- 2005-12-21 EP EP09007812A patent/EP2111859A1/de not_active Withdrawn
- 2005-12-21 AU AU2005322183A patent/AU2005322183B2/en not_active Ceased
- 2005-12-21 US US11/793,941 patent/US8153621B2/en not_active Expired - Fee Related
- 2005-12-21 WO PCT/US2005/046654 patent/WO2006071740A2/en active Application Filing
- 2005-12-21 PL PL05855247T patent/PL1833473T3/pl unknown
- 2005-12-21 SG SG200908557-2A patent/SG158168A1/en unknown
- 2005-12-21 ES ES05855247T patent/ES2331656T3/es active Active
- 2005-12-21 PT PT05855247T patent/PT1833473E/pt unknown
- 2005-12-21 AT AT05855247T patent/ATE442135T1/de active
- 2005-12-21 NZ NZ589951A patent/NZ589951A/xx not_active IP Right Cessation
- 2005-12-21 SI SI200530865T patent/SI1833473T1/sl unknown
- 2005-12-21 DK DK05855247T patent/DK1833473T3/da active
- 2005-12-21 EA EA201100129A patent/EA201100129A1/ru unknown
- 2005-12-21 DE DE602005016601T patent/DE602005016601D1/de active Active
- 2005-12-21 JP JP2007548479A patent/JP4886700B2/ja not_active Expired - Fee Related
- 2005-12-21 EP EP10010050A patent/EP2322162A1/de not_active Withdrawn
- 2005-12-21 KR KR1020147005776A patent/KR101519441B1/ko not_active IP Right Cessation
-
2007
- 2007-05-30 IL IL183565A patent/IL183565A0/en unknown
- 2007-06-22 ZA ZA200705165A patent/ZA200705165B/xx unknown
- 2007-10-16 HK HK07111115.0A patent/HK1102766A1/xx not_active IP Right Cessation
-
2009
- 2009-11-12 CY CY20091101197T patent/CY1109629T1/el unknown
- 2009-12-02 HR HR20090641T patent/HRP20090641T1/hr unknown
-
2012
- 2012-03-12 US US13/418,151 patent/US8546378B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/619,179 patent/US20130217677A1/en not_active Abandoned
-
2014
- 2014-04-23 US US14/259,748 patent/US20150087634A1/en not_active Abandoned
-
2015
- 2015-04-27 IL IL238479A patent/IL238479A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090641T1 (hr) | Pripravci modulatora 5ht2c receptora i postupci uporabe | |
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| HRP20151425T1 (hr) | Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe | |
| KR102477187B1 (ko) | 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 | |
| ES2330113T3 (es) | Uso de compuestos antagonistas crth2 en terapia. | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| CN101595105B (zh) | 作为scd抑制剂的2-取代的5元杂环化合物 | |
| JP2008525480A5 (de) | ||
| HRP20160292T1 (hr) | Derivati 1-fenil-2-piridinilalkil-alkohola kao inhibitori fosfodiesteraze | |
| US20140066466A1 (en) | Necroptosis Inhibitors and Methods of Use Therefor | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| JP2007530694A5 (de) | ||
| DK1045830T3 (da) | Alfa-aminoamidderivater, der er anvendelige som analgetiske midler | |
| NO20054791D0 (no) | Forbindelser for behandling av stoffskiftesykdommer | |
| CA2589438C (en) | Treatment of inflammatory bowel disease | |
| JP2007508358A5 (de) | ||
| JP2015529229A5 (de) | ||
| JP2015524450A5 (de) | ||
| RU2015135722A (ru) | Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение | |
| JP2015502371A5 (de) | ||
| HRP20140326T1 (hr) | Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat | |
| WO2021175283A1 (zh) | 新型ep4拮抗剂的合成及其在癌症和炎症中的用途 | |
| BRPI0707538A2 (pt) | derivados de amida heterobicìclica | |
| KR20200118037A (ko) | 암 또는 염증성 질환들을 치료하기 위한 헤테로비시클릭 카르복시산들 | |
| DK1242406T3 (da) | Hidtil ukendte forbindelser |